O6-methylguanine-DNA methyltransferase activity, p53 gene status and BCNU resistance in mouse astrocytes

Carcinogenesis

Volumn 20, Issue 12, 1999, Pages 2361-2365

  Nutt, Catherine L ^a,b,d   Loktionova, Natasha A ^c   Pegg, Anthony E ^c   Chambers, Ann F ^a,b   Cairncross, J Gregory ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NITROSOUREA; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; ASTROCYTE; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE; CONTROLLED STUDY; DNA REPAIR; ENZYME ACTIVITY; GENE CONTROL; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0033377369     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/20.12.2361     Document Type: Article

References (63)

1. Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B. and Craig, R.W. (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51, 6304-6311.
2. Kuerbitz, S.J., Plunkett, B.S., Walsh, W.V. and Kastan, M.B. (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl Acad. Sci. USA, 89, 7491-7495.
3. Livingstone, L.R., White, A., Sprouse, J., Livanos, E., Jacks, T. and Tlsty, T.D. (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell. 70, 923-935.
4. Yin, Y., Tainsky, M.A., Bischoff, F.Z., Strong, L.C. and Wahl, G.M. (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70, 937-948.
5. Clarke, A.R., Purdie, C.A., Harrison, D.J., Morris, R.G., Bird, C.C., Hooper, M.L. and Wyllie, A.H. (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways [see comments]. Nature, 362, 849-852.
6. Lowe, S.W., Ruley, H.E., Jacks, T. and Housman, D.E. (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957-967.
7. Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A. and Jacks, T. (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes [see comments]. Nature, 362, 847-849.
8. Polyak, K., Xia, Y. Zweier, J.L., Kinzler, K.W. and Vogelstein, B. (1997) A model for p53-induced apoptosis. Nature, 389, 300-305.
9. Chin, K.V., Ueda, K., Pastan, I. and Gottesman, M.M. (1992) Modulation of activity of the promoter of the human MDRI gene by Ras and p53. Science, 255, 459-462.
10. Zastawny, R.L., Salvino, R., Chen, J., Benchimol, S. and Ling, V. (1993) The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene, 8, 1529-1535.
11. Nguyen, K.T., Liu, B., Ueda, K., Gottesman, M.M., Pastan, I. and Chin, K.-V. (1994) Transactivation of the human multidrug resistance (MDRI) gene promoter by p53 mutants. Oncol. Res., 6, 71-77.
12. Xiao, H., Pearson, A., Coulombe, B., Truant, R., Zhang, S., Regier, J.L., Triezenberg, S.J., Reinberg, D., Flores, O., Ingles, C.J. and Greenblatt, J. (1994) Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53. Mol. Cell. Biol., 14, 7013-7024.
13. Wang, P., Reed, M., Wang, Y., Mayr, G., Stenger, J.E., Anderson, M.E., Schwedes, J.F. and Tegtmeyer, P. (1994) p53 domains: structure, oligomerization and transformation. Mol. Cell. Biol., 14, 5182-5191.
14. Goldsmith, M.E., Gudas, J.M., Schneider, E. and Cowan, K.H. (1995) Wild-type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J. Biol. Chem., 270, 1894-1898.
15. Strauss, B.E. and Haas, M. (1995) The region 3′ to the major transcriptional start site of the MDRI downstream promoter mediates activation by a subset of mutant p53 proteins. Biochem. Biophys. Res. Commun., 217, 333-340.
16. Wang, X.W., Yeh, H., Schaeffer, L., Roy, R., Moncollin, V., Egly, J.-M., Wang, Z., Freidberg, E.C., Evans, M.K., Taffe, B.G., Bohr, V.A., Weeda, G., Hoeijmakers, J.H.J., Forrester, K. and Harris, C.C. (1995) p53 modulation of TFIIH-associated nucleotide excision repair activity. Nature Genet., 10, 188-195.
17. 6-methylguanine-DNA methyltransferase gene. Cancer Res., 56, 2029-2032.
18. Leveillard, T., Andera, L., Bissonnette, N., Schaeffer, L., Bracco, L., Egly, J.M. and Wasylyk, B. (1996) Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO J., 15, 1615-1624.
19. 6-alkylguanine-DNA-alkyltransferase in response to ionising radiation is p53 gene dose dependent. Oncogene, 12, 693-697.
20. Scherer, S.J., Welter, C., Zang, K.D. and Dooley, S. (1996) Specific in vitro binding of p53 to the promoter region of the human mismatch repair gene hMSH2. Biochem. Biophys. Res. Commun., 221, 722-728.
21. Ford, J.M. and Hanawalt, P.C. (1997) Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. J. Biol. Chem., 272, 28073-28080.
22. 6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents. Oncogene, 17, 845-851.
23. Wang, Q. and Beck, W.T. (1998) Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res., 58, 5762-5769.
24. Nigro, J.M., Baker, S.J., Preisinger, A.C., Jessup, J.M., Hostetter, R., Cleary, K., Bigner, S.H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F.S., Weston, A., Modali, R., Harris, C.C. and Vogelstein, B. (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature, 342, 705-708.
25. Chung, R., Whaley, J., Kley, N., Anderson, K., Louis, D., Menon, A., Hettlich, C., Freiman, R., Hedley Whyte, E.T., Martuza, R., Jenkins, R., Yandell, D. and Seizinger, B.R. (1991) TP53 gene mutations and 17p deletions in human astrocytomas. Genes Chromosomes Cancer, 3, 323-331.
26. Louis, D.N., von Deimling, A., Chung, R.Y., Rubio, M.P., Whaley, J.M., Eibl, R.H., Ohgaki, H., Wiestler, O.D., Thor, A.D. and Seizinger, B.R. (1993) Comparative study of p53 gene and protein alterations in human astrocytic tumors. J. Neuropathol. Exp. Neurol., 52, 31-38.
27. Louis, D.N. (1994) The p53 gene and protein in human brain tumors. J. Neuropathol. Exp. Neurol., 53, 11-21.
28. van Meyel, D.J., Ramsay, D.A., Casson, A.G., Keeney, M., Chambers, A.F. and Cairncross, J.G. (1994) p53 mutation, expression and DNA ploidy in evolving gliomas: evidence for two pathways of progression. J. Natl Cancer Inst., 86, 1011-1017.
29. Chang, C.H., Horton, J., Schoenfeld, D., Salazer, O., Perez Tamayo, R., Kramer, S., Weinstein, A., Nelson, J.S. and Tsukada, Y. (1983) Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer, 52, 997-1007.
30. Nelson, D.F., Diener West, M., Horton, J., Chang, C.H., Schoenfeld, D. and Nelson, J.S. (1988) Combined modality approach to treatment of malignant gliomas - re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. Natl Cancer Inst. Monogr., 6, 279-284.
31. Grant, R., Liang, B.C., Page, M.A., Crane, D.L., Greenberg, H.S. and Junck, L. (1995) Age influences chemotherapy response in astrocytomas. Neurology, 45, 929-933.
32. Janzer, R.C. and Raff, M.C. (1987) Astrocytes induce blood-brain barrier properties in endothelial cells. Nature, 325, 253-257.
33. Nutt, C.L., Chambers, A.F. and Cairncross, J.G. (1996) Wild-type p53 renders mouse astrocytes resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea despite the absence of a p53-dependent cell cycle arrest. Cancer Res., 56, 2748-2751.
34. 6-alkylguanine DNA repair activity during continuous exposure to carcinogen. Proc. Natl Acad. Sci. USA, 79, 5499-5502.
35. 6-methylguanine. Mol. Cell. Biol., 5, 3293-3296.
36. 6-alkylguanines increases sensitivity to the cytotoxic effects of alkylating agents. Biochem. Biophys. Res. Commun., 132, 178-185.
37. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc. Natl Acad. Sci. USA, 87, 5368-5372.
38. 6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis, 12, 1857-1867.
39. 6-alkylguanine DNA alkyltransferase activity and sensitivity to procarbazine in human brain tumors. Cancer, 75, 1339-1342.
40. Donehower, L.A., Harvey, M., Slagle, B.L., McArthur, M.J., Montgomery, C.A.Jr, Butel, J.S. and Bradley, A. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 356, 215-221.
41. McCarthy, K.D. and De Vellis, J. (1980) Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J. Cell Biol., 85, 890-902.
42. Timme, T.L. and Thompson, T.C. (1994) Rapid allelotype analysis of p53 knockout mice. Biotechniques, 17, 460, 462-463.
43. 6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. Cancer Commun., 2, 371-377.
44. 6-alkylguanine pretreatment on the sensitivity of human colon tumor cells to the cytotoxic effects of chloroethylating agents. Cancer Res., 46, 4500-4504.
45. Sambrook, J., Fritsch, E.F. and Manialis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
46. Edwards, D.R. and Denhardt, D.T. (1985) A study of mitochondrial and nuclear transcription with cloned cDNA probes. Exp. Cell Res., 157, 127-143.
47. Edwards, D.R., Parfett, C.L.J. and Denhardt, D.T. (1985) Transcriptional regulation of two serum-induced RNAs in mouse fibroblasts: equivalence of one species to B2 repetitive elements. Mol. Cell. Biol., 5, 3280-3288.
48. Schmid, P., Lorenz, A., Hameister, H. and Montenarh, M. (1991) Expression of p53 during mouse embryogenesis. Development, 113, 857-865.
49. Komarova, E.A., Chernov, M.V., Franks, R., Wang, K., Armin, G., Zelnick, C.R., Chin, D.M., Bacus, S.S., Stark, G.R. and Gudkov, A.V. (1997) Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J., 16, 1391-1400.
50. Cole, S.P.C. (1986) Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. Cancer Chemother. Pharmacol., 17, 259-263.
51. 6-Methylguanine methyltransferase activity is increased in rat tissues by ionising radiation. Carcinogenesis, 6, 1699-1702.
52. 6-alkylguanine-DNA alkyltransferase activity in fetal rat brain and liver and the induction of CNS tumours. Carcinogenesis, 11, 219-222.
53. 6-methylguanine-DNA methyltransferase in mammalian cells by DNA-damaging treatments. Mol. Cell. Biol., 11, 4660-4668.
54. 6-methylguanine-DNA methyltransferase in mammalian cells. Cancer Res., 52, 1804-1809.
55. 6-alkylguanine-DNA-alkyltransferase mRNA and activity in mouse tissues. Carcinogenesis, 14, 679-683.
56. Grombacher, T., Mitra, S. and Kaina, B. (1996) Induction of the alkyltransferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of base excision repair genes. Carcinogenesis, 17, 2329-2336.
57. 6-methylguanine-DNA methyltransferase to resistance to 1,3-(2-chloroethyl)-1-nitrosourea in human brain tumor-derived cell lines. Mol. Carcinog., 13, 81-88.
58. 6-methylguanine-DNA methyltransferase to monofunctional alkylating-agent resistance in human brain tumor-derived cell lines. Mol. Carcinog., 13, 70-80.
59. 6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin. Cancer Res., 2, 735-741.
60. 6-methylguanine-DNA methyltransferase levels and clinical response iduced by chloroethylnitrosourea therapy in glioma patients. Can. J. Neurol. Sci., 26, 104-109.
61. Hun Rhee, C. Ruan, S., Chen, S., Chenchik, A., Levin, V.A., Yung, A.W.K., Fuller, G.N. and Zhang, W. (1999) Characterization of cellular pathways involved in glioblastoma response to the chemotherapeutic agent 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) by gene expression profiling. Oncol. Rep., 6, 393-401.
62. Kirches, E., Scherlach, C., von Bossanyi, P., Schneider, T., Szibor, R., Kutz, E., Warich-Kirches, M. and Dietzmann, K. (1999) MGMT- and P450 3A-inhibitors do not sensitize glioblastoma cell cultures against nitrosoureas. Clin. Neuropathol., 18, 1-8.
63. 6-methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bischloroethylnitrosourea: A Southwest Oncology Group Study. J. Clin. Oncol., 16, 3310-3315.